Annual report pursuant to Section 13 and 15(d)

Reverse Merger - Additional Information (Detail)

v3.19.1
Reverse Merger - Additional Information (Detail)
$ / shares in Units, $ in Thousands
12 Months Ended
May 23, 2018
Aug. 01, 2017
Year
Right
$ / shares
shares
Dec. 31, 2017
USD ($)
shares
Dec. 31, 2018
shares
Business Acquisition [Line Items]        
Reverse stock split ratio 0.1      
Common stock, shares outstanding | shares     1,194,793 6,721,117
Contingent value rights recovery | $     $ 200  
OncoGenex Pharmaceuticals, Inc [Member]        
Business Acquisition [Line Items]        
Reverse stock split ratio   0.0909    
Share price | $ / shares   $ 46.20    
Common stock, shares outstanding | shares   273,670    
Number of contingent value rights to be issued for each share of common stock outstanding | Right   1    
OncoGenex Pharmaceuticals, Inc [Member] | Contingent Value Rights [Member]        
Business Acquisition [Line Items]        
Combined company acquisition period results   5 years    
Aggregate consideration distributed to the holders, consideration received percent   80.00%    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Price [Member] | Warrant [Member]        
Business Acquisition [Line Items]        
Fair value of outstanding warrants, assumptions   46.20    
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Fair value of outstanding warrants, assumptions   1.32    
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Fair value of outstanding warrants, assumptions   1.53    
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Fair value of outstanding warrants, assumptions   1 year 10 months 28 days    
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Fair value of outstanding warrants, assumptions   3 years 2 months 26 days    
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Fair value of outstanding warrants, assumptions   90.33    
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Fair value of outstanding warrants, assumptions   106.08    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Stock Price [Member]        
Business Acquisition [Line Items]        
Fair value of stock options, assumptions   46.20    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Fair value of stock options, assumptions   97.23    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Fair value of stock options, assumptions   106.63    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Fair value of stock options, assumptions   1.31    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Fair value of stock options, assumptions   1.54    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Fair value of stock options, assumptions | Year   1.82    
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Fair value of stock options, assumptions | Year   3.31